North Dakota State Investment Board Purchases Shares of 7,756 Elevance Health, Inc. $ELV

North Dakota State Investment Board purchased a new stake in Elevance Health, Inc. (NYSE:ELV) during the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 7,756 shares of the company’s stock, valued at approximately $2,719,000.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Elyxium Wealth LLC acquired a new position in Elevance Health in the fourth quarter valued at about $58,000. Leuthold Group LLC acquired a new position in Elevance Health in the fourth quarter valued at about $7,898,000. May Hill Capital LLC acquired a new position in Elevance Health in the fourth quarter valued at about $240,000. AlphaCore Capital LLC boosted its position in Elevance Health by 166.1% in the fourth quarter. AlphaCore Capital LLC now owns 2,850 shares of the company’s stock valued at $999,000 after buying an additional 1,779 shares in the last quarter. Finally, DNB Asset Management AS boosted its position in Elevance Health by 75.8% in the fourth quarter. DNB Asset Management AS now owns 74,306 shares of the company’s stock valued at $26,048,000 after buying an additional 32,048 shares in the last quarter. 89.24% of the stock is currently owned by institutional investors and hedge funds.

Elevance Health Trading Up 0.2%

Shares of NYSE ELV opened at $393.35 on Tuesday. Elevance Health, Inc. has a 1-year low of $273.71 and a 1-year high of $412.96. The company has a market cap of $85.42 billion, a PE ratio of 16.73, a P/E/G ratio of 2.23 and a beta of 0.66. The company has a current ratio of 1.48, a quick ratio of 1.48 and a debt-to-equity ratio of 0.70. The company has a 50-day moving average of $325.02 and a two-hundred day moving average of $334.34.

Elevance Health (NYSE:ELV) last announced its earnings results on Wednesday, April 22nd. The company reported $12.58 earnings per share for the quarter, topping analysts’ consensus estimates of $10.74 by $1.84. Elevance Health had a net margin of 2.62% and a return on equity of 15.58%. The company had revenue of $49.49 billion during the quarter, compared to the consensus estimate of $48.21 billion. During the same period in the previous year, the firm posted $11.97 earnings per share. The company’s revenue was up 1.5% on a year-over-year basis. Elevance Health has set its FY 2026 guidance at 19.850- EPS. As a group, equities analysts expect that Elevance Health, Inc. will post 26.79 earnings per share for the current fiscal year.

Elevance Health Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Thursday, June 25th. Stockholders of record on Wednesday, June 10th will be paid a $1.72 dividend. This represents a $6.88 annualized dividend and a dividend yield of 1.7%. The ex-dividend date of this dividend is Wednesday, June 10th. Elevance Health’s dividend payout ratio (DPR) is 29.26%.

Wall Street Analyst Weigh In

ELV has been the topic of a number of recent analyst reports. Guggenheim boosted their price target on shares of Elevance Health from $396.00 to $399.00 and gave the company a “buy” rating in a research report on Friday, April 24th. Jefferies Financial Group reduced their price target on shares of Elevance Health from $395.00 to $391.00 and set a “buy” rating on the stock in a research report on Monday, April 20th. Deutsche Bank Aktiengesellschaft boosted their price target on shares of Elevance Health from $332.00 to $363.00 and gave the company a “hold” rating in a research report on Thursday, April 23rd. Weiss Ratings upgraded shares of Elevance Health from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Friday, April 24th. Finally, Sanford C. Bernstein boosted their target price on shares of Elevance Health from $384.00 to $424.00 and gave the stock an “outperform” rating in a research note on Friday, April 24th. Thirteen research analysts have rated the stock with a Buy rating and ten have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $384.58.

About Elevance Health

Elevance Health, Inc (NYSE: ELV) is a large U.S.-based health benefits company that provides a broad range of health insurance products and related services. Headquartered in Indianapolis, the company rebranded from Anthem, Inc to Elevance Health in 2022 while continuing to operate consumer-facing health plans under established state and national brands. Gail Boudreaux serves as chief executive officer and president, leading the company’s strategic focus on integrated health care and benefit delivery.

Elevance’s core activities include offering medical and specialty health plans for individuals, employers and government programs, including Medicare and Medicaid managed-care products.